-

ASAM and OpenEvidence Partner to Expand Access to Evidence-Based Addiction Medicine Guidance

Collaboration brings ASAM’s clinical guidelines and implementation resources to the point of care for the millions of clinicians who use OpenEvidence.

MIAMI & ROCKVILLE, Md.--(BUSINESS WIRE)--The American Society of Addiction Medicine (ASAM) and OpenEvidence, the most popular AI for doctors in the United States, today announced a collaboration to make ASAM’s clinical guidelines, guidance, and implementation resources accessible through OpenEvidence. This integration enables OpenEvidence’s clinician users to readily access ASAM’s evidence-based guidance for the care of patients with substance use disorders (SUD) and addiction. ASAM’s guidance will surface automatically when clinically relevant, alongside peer-reviewed literature, with citations and a direct link back to the source.

Through this collaboration, clinicians can rapidly surface and review addiction medicine clinical guidelines and guidance from ASAM. In 2025, 44.6 million Americans had a substance use disorder in the past year, demonstrating an urgent need to continue expanding access to clinical resources that support evidence-based practices for the treatment and prevention of SUD as well as behavioral addictions.

“ASAM’s clinical practice guidelines aim to equip clinicians with high-quality, science-based guidance to support the care of patients with addiction and facilitate a path to long-term health and recovery,” said Stephen M. Taylor, MD, MPH, president of the American Society of Addiction Medicine. “Through this collaboration, we hope to make ASAM’s evidence-based treatment guidance more accessible to all healthcare professionals who may provide care for patients with addiction.”

“Addiction encompasses a wide range of conditions that clinicians encounter daily, yet too often, evidence-based guidance isn’t at hand when a treatment decision is being made,” said Isabel Ostrer, Director of Primary Care Initiatives. “ASAM sets the standard of care in addiction medicine. Bringing its guidelines directly to the point of care means every clinician, wherever they practice, can offer patients with substance use disorders care grounded in the best available evidence.”

About the American Society of Addiction Medicine

The American Society of Addiction Medicine (ASAM), founded in 1954, is a professional medical society representing over 8,000 physicians, clinicians, and associated professionals in the field of addiction medicine. ASAM is dedicated to increasing access and improving the quality of addiction treatment, educating physicians and the public, supporting research and prevention, and promoting the appropriate role of physicians in the care of patients with addiction. For more information, visit www.ASAM.org.

About OpenEvidence

OpenEvidence is the most popular AI for doctors in the United States. According to independent studies, more American physicians use OpenEvidence than all other AI platforms combined. OpenEvidence is trusted by millions of verified U.S. healthcare professionals making high-stakes clinical decisions at the point of care, with evidence that is sourced, cited, and grounded in peer-reviewed medical literature. Founded with the mission to organize and expand the world's collective medical knowledge, OpenEvidence is now used daily, on average, by the majority of physicians in the United States. OpenEvidence is free for all verified U.S. clinicians. Learn more at openevidence.com.

Contacts

Media Contacts
Sarah Shelson, 301-547-4110, sshelson@ASAM.org
OpenEvidence, media@openevidence.com

OpenEvidence

Details
Headquarters: Miami, FL
CEO: Daniel Nadler
Employees: na
Organization: PRI

Release Versions

Contacts

Media Contacts
Sarah Shelson, 301-547-4110, sshelson@ASAM.org
OpenEvidence, media@openevidence.com

Social Media Profiles
More News From OpenEvidence

American College of Rheumatology and OpenEvidence Collaborate to Expand Access to Trusted Patient Education Resources

MIAMI & ORLANDO, Fla.--(BUSINESS WIRE)--The American College of Rheumatology (ACR), the professional organization representing more than 10,600 rheumatology professionals worldwide, and OpenEvidence, the most widely used medical AI platform among U.S. physicians, today announced a collaboration at ACR Convergence 2026 to make ACR’s patient education resources available within OpenEvidence, helping rheumatologists, as well as primary care physicians and other specialists managing rheumatic condi...

Announcing Learn: OpenEvidence's Personalized Medical Education Platform

MIAMI--(BUSINESS WIRE)--OpenEvidence, the most popular AI for doctors in the United States, today launched Learn: a free, personalized medical education platform built to support trainees and clinicians across their entire careers. As AI transforms work, it has never been more important to ensure the technology strengthens learning as well. OpenEvidence has been widely adopted by clinicians as an essential tool at the point of care, and is now applying that same technology to reimagine not just...

OpenEvidence and NYU Langone Health Partner to Bring Patient-Aware Intelligence to 12 Million Visits in New York City

MIAMI & NEW YORK--(BUSINESS WIRE)--NYU Langone Health, one of the nation’s premier academic health systems and ranked No.1 in the nation for quality by Vizient, Inc., and OpenEvidence, the most popular AI for doctors in the United States, today announced a collaboration to bring OpenEvidence directly into NYU Langone’s Epic electronic health record (EHR), with Patient Aware Clinical Intelligence. Clinicians across NYU Langone will now be able to ask complex clinical questions in natural languag...
Back to Newsroom